Pfizer (PFE) Long-Term Deferred Tax (2009 - 2026)

Pfizer (PFE) has 18 years of Long-Term Deferred Tax data on file, last reported at $10.0 billion in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $10.0 billion, up 4.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.0 billion (up 4.43% YoY), and the FY2025 annual result was $9.7 billion, up 11.97% from the prior year.
• Long-Term Deferred Tax improved to $10.0 billion in Q1 2026 per PFE's latest filing, from $9.7 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $11.0 billion in Q3 2025 and troughed at $3.7 billion in Q4 2023.
• A 5-year average of $7.9 billion and a median of $7.9 billion in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax jumped 159.91% in 2022, then tumbled 44.63% in 2023.
• A 5-year view of Long-Term Deferred Tax shows it stood at $6.7 billion in 2022, then plunged by 44.63% to $3.7 billion in 2023, then surged by 133.73% to $8.7 billion in 2024, then rose by 11.97% to $9.7 billion in 2025, then rose by 2.74% to $10.0 billion in 2026.
• Business Quant data shows PFE's Long-Term Deferred Tax at $10.0 billion in Q1 2026, $9.7 billion in Q4 2025, and $11.0 billion in Q3 2025.